ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
Man lost 54 Kgs in 6 months with MGB procedure
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
New deal strengthens Congenica’s presence in India
Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
Subscribe To Our Newsletter & Stay Updated
